HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
Cardio 2022

Dae Wook Lee

Dae Wook Lee, Speaker at Heart Conferences
Novartis, Korea, Republic of
Title : Powering Biopharma research with Data and Genomics – the time is now


The human genetic techniques including Coding GWAS are generically associated with diseases whereas the expansion of Human Data Ecosystem in multi-geographic regions provide valuable insights on disease specific cohorts and genomic data. The investment on human genome research and analytics based on The rapid success of using human big data has been a novel trend for drug development and discovery. health records is expanding globally, with a more strategic approach to accessing human data. The research into Big Human Data Investment has their continuing synergistic influence for testing or generation and validation of hypothesis from the understanding of diseases to experimental validation in human samples and data.

In addition, the data from population specific variants could identify novel genetic associations with diseases, and also, the compilation of big data has a huge impact on the pharmaceutical industry’s research methods by using rapid analysis on demand with sufficient statistical power to derive future potential hypotheses. Since the deliverable from biobank analysis provides both disease risk and safety in the general population, the Biobank scale genomic data identifies rare variants such as the Loss of Function (LoF) variant that is associated with health.

In subgroups, the functional variants (Missense, LoF) accelerate medical development by reinforcing already validated and enriched genomic data sets where the potential of providing the opportunities for new drug indications and discovery. With more innovation and evolution we are closer to greater successes in the generation of diverse population genome data and at the same time deriving safety information and discovering new indications for drugs.

Key Words: Genomic research, Human genetic techniques, Human Data Ecosystem, Drug development



Dr. Dae Wook Lee is a Medical Director of Novartis Korea in Cardiology, Renal, Metabolism, and Gene Therapy. He was Head of Medical Portfolio Management in Rare disease, Gastroenterology, PDT, Neuroscience and New Molecular entities from the Asia-Pacific Region of Takeda Pharmaceutical Ltd Pte. Dae Wook Lee obtained his Medical Degree from the University of Warwick, U.K. awarded MbChB Medicine & Surgery, and completed MSC Genetic Epidemiology at the Medical Research Unit in the University of Sheffield, U.K with an additional BSc Biomedical Science degree. He is currently an Executive Master of Business Administration (MBA) Candidate for Harris College of Business, Faulkner University in North Alabama in U.S. Dae Wook received the Best Research Award in the International Research Awards of Cardiology and Cardiovascular Medicine in 2022.

Dr. Dae Wook Lee’s main clinical research interests lie in genetics and novel medical statistical analysis of Rare Diseases including Cardiology, Rare Hematology, Rare Metabolic Diseases including Fabry & Gaucher’s Disease, Rare Immunology including Hereditary AngioEdema (HAE), etiology and pathophysiology of inflammatory bowel disease (IBD), and Rare Neuroscience disease including Paediatric Epilepsy and Narcolepsy Type 1. One of his recent publications includes Network Meta-analysis of Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients, and Retrospective analysis of Ulcerative Colitis Real-world Evidence implementing exploratory Propensity Score Matching (PSM) Analysis. Dr. Dae Wook Lee is also a member of Korean Society of Pharmaceutical Medicine (KSPM)